The Hole Story: Interatrial Shunt Companies Are—Mostly—Pushing Ahead tctmd.com/news/hole-stor… (Chris Meduri, MD MPH Corvia Medical, Inc. vwavemedical Gregg W. Stone MD Edwards Lifesciences Alleviant Medical)

“Transitions are opportunities. They are full of possibilities, marking a juncture that combines an end and a beginning. For JACC Journals, the editorial transition is a moment to honor the past and seize the potential of the future.” My Editor’s page. jacc.org/doi/10.1016/j.…

In front of the building of your hospital are there HCP smoking? Soc Esp Cardiología Sici GISE European Society of Cardiology SCAI Now EAPCIPresident PCRonline 🫀

Apixaban May Have Advantages in Patients With Liver Cirrhosis and AF tctmd.com/news/apixaban-…

Spoke with Zoomer Magazine today: thrilling to be on the other side of the microphone! Two weeks to go for #TheLeapYearGene & #TheLeapYearGeneofKitMcKinley. Preorders, anyone? unionsquareandco.com/9781454956297/… harpercollins.ca/9781443473163/… ⁦Union Square & Co.⁩ ⁦HarperCollinsCa⁩

Guys. The European Society of Cardiology has updated its media policy to say journalists won't have access to the Exhibit area at #ESCongress. Some questions. 1) Where will I get free caffeine/chocolates/pens? 2) What the heck is industry planning on getting up to that we can't watch?

Olympic Hearts: Screening for CVD Among Team USA’s Athletes tctmd.com/news/olympic-h…

“The key to providing good care from a national team perspective is establishing a comprehensive multidisciplinary medical team with good communication from across all disciplines,” #ACCSportsCardio member Sports & Performance Cardiology told TCTMD. Read more: bit.ly/3SBEh2v #Paris2024

Thoroughly enjoyed interviewing Shelley Wood (she/her) about her new novel THE LEAP YEAR GENE! Here is my write-up in Zoomer Magazine. You can catch Shelley Wood (author of THE QUINTLAND SISTERS) live on August 18 at the Sunshine Coast Sunshine Coast Festival of the Written Arts. everythingzoomer.com/zed-book-club/…

Look how the leading causes of death in the US have changed over the past 4 years JAMA jamanetwork.com/journals/jama/…

DES Best for In-Stent Restenosis, but DCBs Also Viable tctmd.com/news/des-best-…

‘Disproportionate’ Suicide/Self-Harm Signal With Semaglutide: WHO Database tctmd.com/news/dispropor…

Thanks to Roger S. McIntyre, MD, FRCPC and Georgios Schoretsanitis -- a signal with semaglutide, no cause for alarm, but something that warrants further study, say the experts.

Regarding kidney & CV outcomes, researchers found no significant difference between #SGLT2 or GLP-1 receptor agonist treatment in patients with #Diabetes. These findings were published in #JACC. bit.ly/3MgrD5z TCTMD Michael O'Riordan

ACC Media Center JACC Journals Michael O'Riordan Great to see clarification on antithrombotic strategies for afib patients who've experienced cvACS or undergone PCI. P2Y12 inhibitor and DOAC without aspirin seems to be the way forward.

Surprising findings from the #ABYSS trial: Stopping beta-blockers post-MI may be harmful. Discontinuation failed to meet noninferiority for all-cause mortality, nonfatal MI, stroke, or CV hospitalizations compared to continuation. Michael O'Riordan TCTMD Mamas A. Mamas

#ACCPVD Past Chair Dr. Marc Bonaca MD MPH said ABYSS suggests there is benefit to continuing beta-blocker therapy in patients with a prior #cvMI and preserved ejection fraction. Check out more from Michael O'Riordan: bit.ly/3MxFEvz #ESCCongress

Two important #presentations from my Polish team today at the #ESCCongress: 👉The first one on the #RWE data from the #PMMHRI-#FH #Registry that clearly showed that we diagnose FH too late (in adults at the mean age of 44 and in children at the age of 9 yrs), that statin and

MHO of NOTION-3, not so hot about changing practice… tctmd.com/news/notion-3-… thx Michael O'Riordan TCTMD for the opportunity to voice things out while on-call during long WE! Mamas A. Mamas

Thank you Michael O'Riordan TCTMD for the interview on the results of this interesting paper. To TCTMD, Banach pointed out that the use of #statin #therapy plus #ezetimibe early was confirmed in the #RACING trial. In that study, upfront #combination therapy in patients with